PROGRAMMED CELL DEATH 1 LIGAND 1 EXPRESSION AND ASSOCIATION WITH SURVIVAL IN MESOTHELIOMA

被引：0
|
作者：
Mansfield, A. S. [1 ]
Peikert, T. [1 ]
Roden, A. [1 ]
Krco, C. [1 ]
Harrington, S. [1 ]
Dong, H. [1 ]
Kwon, E. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2014年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
127O
引用
收藏
页码：S50 / S50
页数：1
相关论文
共 50 条
  • [31] Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
    Kwon, Dohee
    Kim, Sehui
    Kim, Pil-Jong
    Go, Heounjeong
    Nam, Soo Jeong
    Paik, Jin Ho
    Kim, Young A.
    Kim, Tae Min
    Heo, Dae Seog
    Kim, Chul Woo
    Jeon, Yoon Kyung
    HISTOPATHOLOGY, 2016, 68 (07) : 1079 - 1089
  • [32] Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas
    Liu, Yang
    Ma, Jing
    Yu, Kangjie
    Li, Mingyang
    Liu, Fang
    Yan, Qingguo
    Wang, Zhe
    Guo, Shuangping
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (04) : 507 - 512
  • [33] Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent
    van Erp, Anke E. M.
    Versleijen-Jonkers, Yvonne M. H.
    Hillebrandt-Roeffen, Melissa H. S.
    van Houdt, Laurens
    Gorris, Mark A. J.
    van Dam, Laura S.
    Mentzel, Thomas
    Weidema, Marije E.
    Savci-Heijink, C. Dilara
    Desar, Ingrid M. E.
    Merks, Hans H. M.
    van Noesel, Max M.
    Shipley, Janet
    van der Graaf, Winette T. A.
    Flucke, Uta E.
    Meyer-Wentrup, Friederike A. G.
    ONCOTARGET, 2017, 8 (41) : 71371 - 71384
  • [34] Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    Bomze, David
    Azoulay, Daniel
    Meirson, Tomer
    JAMA ONCOLOGY, 2020, 6 (07) : 1114 - 1115
  • [35] Tumor cell expression of programmed cell death 1 ligand 1 is a prognostic factor for malignant melanoma
    Hino, R.
    Kabashima, K.
    Kato, Y.
    Yagi, H.
    Nakamura, M.
    Honjo, T.
    Okazaki, T.
    Tokura, Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S43 - S43
  • [36] Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma
    Tamura, Akihiro
    Yoshida, Makiko
    Yamamoto, Nobuyuki
    Nino, Nanako
    Nakatani, Naoko
    Ichikawa, Takayuki
    Nakamura, Sayaka
    Saito, Atsuro
    Kozaki, Aiko
    Kishimoto, Kenji
    Ishida, Toshiaki
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    BLOOD, 2018, 132
  • [37] Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
    Fang, Xiao-Na
    Fu, Li-Wu
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (02) : 141 - 151
  • [38] Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma
    Villasboas, Jose Caetano
    Ansell, Stephen
    CANCER JOURNAL, 2016, 22 (01): : 17 - 22
  • [39] Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
    Debasree Banerjee
    Sean Monaghan
    Runping Zhao
    Thomas Walsh
    Amy Palmisciano
    Gary S. Phillips
    Steven Opal
    Mitchell M. Levy
    Critical Care, 22
  • [40] Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
    Banerjee, Debasree
    Monaghan, Sean
    Zhao, Runping
    Walsh, Thomas
    Palmisciano, Amy
    Phillips, Gary S.
    Opal, Steven
    Levy, Mitchell M.
    CRITICAL CARE, 2018, 22
12345